MedPath

Adriblastina RD

Brand Name: Adriblastina RD

Generic Name: Doxorubicin Hydrochloride

Active
Registration Number

DRP-3413

Dosage Form

Lyophilized Powder for Injection (IV)

Issuance Date

February 9, 2023

Expiry Date

February 9, 2028

Product Information

Philippine FDA product specifications and classification details

Product Specifications

Dosage Strength50 mg
Packaging25 mL-Capacity Type I Colorless Glass Vial with chlorobutyl Rubber stopper and Aluminum Seal with a Polypropylene Flip-off Top (Box of 1's)

Classification

C
Classification
Prescription Drug (RX)
P
Pharmacologic
Antineoplastic (Anthracycline)
A
Application
Initial
Philippine FDA Classification

Active Ingredients (1)

Complete list of active ingredients in this pharmaceutical product.

Doxorubicin HydrochlorideActive
Monograph: Doxorubicin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

MedPath - Medical Intelligence Platform